Limoslactobacillus reuteri 30 capsules (3 billion CFU/capsule)


The use of Limosilactobacillus reuteri probiotics is known for its versatile applications as it serves various health purposes across different conditions. It shows efficacy in alleviating symptoms of respiratory infections in children1 and acts as an adjunct treatment for chronic periodontitis2. Moreover, it enhances the long-term effectiveness of mRNA-based COVID-19 vaccines3 and aids in the treatment of acute uncomplicated diverticulitis4. In addition, it mitigates colic symptoms in infants5 and inhibits H. pylori growth, thereby reducing antibiotic-associated side effects6. This versatile probiotic contributes to managing pregnancy gingivitis7 and decreases episodes and duration of diarrhoea and respiratory tract infections in healthy children8. Furthermore, it reduces salivary S. mutans counts9, alleviates abdominal pain intensity10, and improves early feeding tolerance in preterm infants, promoting growth and shortening hospital stays11. It also modifies inflammatory parameters, alters the gastrointestinal microbiome12, and accelerates nutritional recovery in children with anorexia nervosa13. Lastly, as an adjunct to rehydration therapy, it benefits children with acute gastroenteritis14. Notably, L. reuteri is a prolific producer of vitamin B1215 and reuterin16.


Dosage: 3 billion CFU per capsule

Capsules per order: 30 capsules

Instructions: 1 capsule daily (morning)


  1. Maya-Barrios A, Lira-Hernandez K, Jiménez-Escobar I, Hernández L, Ortiz-Hernandez A, Jiménez-Gutiérrez C, López-Velázquez G, Gutiérrez-Castrellón P. Limosilactobacillus reuteri ATCC PTA 5289 and DSM 17938 as adjuvants to improve evolution of pharyngitis/tonsillitis in children: randomised controlled trial. Benef Microbes. 2021 Apr 12;12(2):137-145.
  2. Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M, Haytac MC. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol. 2013 Nov;40(11):1025-35.
  3. Forsgård RA, Rode J, Lobenius-Palmér K, Kamm A, Patil S, Tacken MGJ, Lentjes MAH, Axelsson J, Grompone G, Montgomery S, Brummer RJ. Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial. Gut Microbes. 2023 Jan-Dec;15(1):2229938.
  4. Ojetti V, Saviano A, Brigida M, Petruzziello C, Caronna M, Gayani G, Franceschi F. Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis. Eur J Gastroenterol Hepatol. 2022 May 1;34(5):496-502.
  5. Fatheree NY, Liu Y, Taylor CM, Hoang TK, Cai C, Rahbar MH, Hessabi M, Ferris M, McMurtry V, Wong C, Vu T, Dancsak T, Wang T, Gleason W, Bandla V, Navarro F, Tran DQ, Rhoads JM. Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Pediatr. 2017 Dec;191:170-178.e2.
  6. Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, Ierardi E, Russo F, Riezzo G, Di Leo A, Cavallo L, Francavilla A, Versalovic J. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol. 2014 May-Jun;48(5):407-13.
  7. Schlagenhauf U, Jakob L, Eigenthaler M, Segerer S, Jockel-Schneider Y, Rehn M. Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT. J Clin Periodontol. 2016 Nov;43(11):948-954.
  8. Gutierrez-Castrellon P, Lopez-Velazquez G, Diaz-Garcia L, Jimenez-Gutierrez C, Mancilla-Ramirez J, Estevez-Jimenez J, Parra M. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics. 2014 Apr;133(4):e904-9.
  9. Alforaidi S, Bresin A, Almosa N, Lehrkinder A, Lingström P. Oral Colonisation after the Administration of Drops Containing Lactobacillus reuteri. Oral Health Prev Dent. 2020 Feb 12;18(1):1017-1023.
  10. Romano C, Ferrau’ V, Cavataio F, Iacono G, Spina M, Lionetti E, Comisi F, Famiani A, Comito D. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014 Oct;50(10):E68-71.
  11. Cui X, Shi Y, Gao S, Xue X, Fu J. Effects of Lactobacillus reuteri DSM 17938 in preterm infants: a double-blinded randomized controlled study. Ital J Pediatr. 2019 Nov 9;45(1):140.
  12. Tenorio-Jiménez C, Martínez-Ramírez MJ, Del Castillo-Codes I, Arraiza-Irigoyen C, Tercero-Lozano M, Camacho J, Chueca N, García F, Olza J, Plaza-Díaz J, Fontana L, Olivares M, Gil Á, Gómez-Llorente C. Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. Nutrients. 2019 Jul 31;11(8):1761.
  13. Žaja O, Fiolić M, Ćuk MC, Tiljak MK. “The role of L. reuteri DSM17938 in nutritional recovery and treatment of constipation in children and adolescents with anorexia nervosa – a randomized, double blind, placebo controlled study”. Clin Nutr ESPEN. 2021 Dec;46:47-53.
  14. Szymański H, Szajewska H. Lack of Efficacy of Lactobacillus reuteri DSM 17938 for the Treatment of Acute Gastroenteritis: A Randomized Controlled Trial. Pediatr Infect Dis J. 2019 Oct;38(10):e237-e242.
  15. Gu Q, Zhang C, Song D, Li P, Zhu X. Enhancing vitamin B12 content in soy-yogurt by Lactobacillus reuteri. Int J Food Microbiol. 2015 Aug 3;206:56-9.
  16. Rodrigues FJ, Cedran MF, Bicas JL, Sato HH. Reuterin-producing Limosilactobacillus reuteri: Optimization of in situ reuterin production in alginate-based filmogenic solutions. Curr Res Food Sci. 2021 Nov 27;4:926-931.